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2Process outline - comparison
Drug
+
Excipients
Hot-melt extrusion
3D printing (FDM)
Tablets
Motivation + advantages
 Adjustable geometry and porosity (=> dissolution rate)
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 Multi-drug loading, multilayer tablets (multiple nozzles)
 Personalized dosing, flexibility
 August 2015 – First commercial application - Spritam
(Levetiracetam) approved by FDA
FDA-approved Spritam tablets FDM-printed tablet
 Potential for scale-up (printhead arrays)
Surface of a FDM tablet 
(SEM)
ZipDoseTechnology
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 First approved 3D-printed dosage form
 High dose of the drug Levetiracetam, immediate release
ZipDoseTechnology
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 First approved 3D-printed dosage form
 High dose of the drug Levetiracetam, immediate release
Solid paste extrusion
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 Easy formulation (drug can be in a dispersion)
 No thermal processing, but time-consuming paste preparation
 Multitablet – up to 5 different drugs with varying release rates
Solid paste extrusion
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Ink-jet 3D printing
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 High resolution (30µm)
 Time-consuming process, friability
 Typically involves solvent evaporation
 Example:
Heated chamber, Fenofibrate + beeswax
Stereolitography (SLA) 
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 Excipients – photo-curable resins => UV radiation
 High resolution (10µm), no external heating
 “Applicable” for most drugs, UV-drug interaction poses risk
Selective light sintering (SLS) 
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 Sintering of excipients + drug in powder form
 Material loss, rinsing step
 Example: Kollicoat IR, Eudragit L100-55 + Paracetamol
Fused deposition modelling
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General filament composition
 Polymer matrix (Soluplus, Eudragit XX, Kollidon XX, cellulose derivates)
- biodegradable approved excipients, solubilize/amorphize the drug
- suitable thermal and rheological properties
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 Functional additives – plasticizers (PEG XX, glycerol, …), 
glidants/anticaking agents (Talcum, MgStearate), disintegrants (Ac-Di-Sol, 
starch), desiccants (citric acid anhydrous)
- affect mechanical properties of the filaments, process temperature, 
properties of the powder form, dissolution / disintegration kinetics
 An approved drug (API)
- thermal stability of the molecule
 Mechanical properties (Young‘s modulus, hardness)
 Shape homogeneity (affected by extrusion parameters)
 Heat transfer rate (heating & cooling)
 Surface roughness / stickiness 
 Lowest achievable process temperature
 Homogeneity of composition (drug content)
 Drug structure (amorphous / crystalline) and stability
 Dissolution / disintegration rate
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Important filament properties
& extrusion parameters
Pharma-grade hot-melt extrusion
 Filament cooling
 Filament conveying
 Powder 
agglomeration
 Cavity formation
=> Anticaking agents (glidants)
Rheology of the powder form
Inner structure of the filaments
 Mechanical properties affected by microporosity (in some
cases up to 40% v/v)
 Micro-CT, Image analysis and reconstruction
 Porosity lowered by adding dessiccants or glidants
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Important filament properties
& extrusion parameters
Printing parameter adjustment
 Gear speed, inner filling characteristics, nozzle movement
speed, filament retraction, perimeter characteristics, …
 Printing temperature, bed temperature, …
 Printing resolution distribution, layer overlap, nozzle distance,
…
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Drug structure analysis
 Amorphous / crystalline after extrusion?
19
=> X-ray powder diffractometry, differential scanning calorimetry
Homogeneity of drug content
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HPLC: 
UV spectroscopy: 
 Absorpce of excipients
 Light scattering
 Solubility
Disintegration enhancement
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=> Effervescent compounds – disintegration due to CO2
production, but leads to increased porosity and
brittleness
„Exploding“ effervescent tablet
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 Hollow tablet filled with effervescent mixture
Virtual prototyping and parametric design
of 3D printed tablets
based on the solution of inverse problem
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1) Parametric series of tablets with varying internal porosities
=> library of dissolution profiles, superpositions
2) Adjusting parameters of a mathematical model to accurately predict
dissolution and intrapolate between measured data
3) Superpositions of different porosities to achieve new release profiles
4) A desired release profile met by iterative programming
=> tablet design and printing, experimental verification
Desired result Initial product parameters
Virtual prototyping and parametric design
of 3D printed tablets
based on the solution of inverse problem
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Virtual prototyping and parametric design
of 3D printed tablets
based on the solution of inverse problem
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Dissolution of single-porosity tablets
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Model overview, parameter fitting
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Model overview, parameter fitting
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Model overview, parameter fitting
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Conclusion
 Parametric study of composition and process parameters led to
achieving FDM printability of 8 drugs
 Products analyzed (homogeneity, drug structure, material porosity, 
powder rheology, mechanical stability, in vitro dissolution, …)
 Dissolution kinetics predicted through mathematical 3D modelling, 
linked to tablet structure
 Employing genetic (evolutional) algorithm to find desired tablet 
structure
 Mapping and predicting “printability” for new drugs
res = 200 µm res = 100 µm
Thank you for your attention
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